Rockefeller Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.6M Sell
31,367
-1,000
-3% -$85.9K 0.01% 1115
2026
Q1
$2.7M Buy
32,367
+6,834
+27% +$541K ﹤0.01% 1167
2025
Q4
$1.99M Buy
25,533
+25,415
+21,538% +$1.72M ﹤0.01% 1251
2025
Q3
$6.68K Buy
+118
New +$5.32K ﹤0.01% 3790
2023
Q1
– Sell
-10,423
Closed -$260K – 3030
2022
Q4
$260K Buy
10,423
+223
+2% +$5.95K ﹤0.01% 1543
2022
Q3
$222K Buy
+10,200
New +$269K ﹤0.01% 1610

Other funds holding KYMR

Rockefeller Capital Management's KYMR Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Kymera Therapeutics (KYMR) stake by 3.1% in Q2 2026, selling an estimated $85.9K and leaving 31,367 shares worth $3.6M. The position accounts for 0.01% of the portfolio, ranked #1115.

Rockefeller Capital Management first reported a position in KYMR in Q3 2022 and has held it in 6 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Rockefeller Capital Management held 31,367 shares of Kymera Therapeutics worth $3.6M as of Q2 2026.
  • Rockefeller Capital Management sold 1,000 Kymera Therapeutics shares in Q2 2026, an estimated $85.9K.
  • Kymera Therapeutics made up 0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1115 holding.
  • Rockefeller Capital Management first reported a position in Kymera Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.